© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer.
Insight on the importance of germline testing and HRD status in ovarian cancer as well as who should be tested.
Thomas Herzog, MD, reviews the statistics of ovarian cancer in the United States in 2020 including survival rates and types of tumors.